Please login to the form below

Not currently logged in
Email:
Password:

PAH

This page shows the latest PAH news and features for those working in and with pharma, biotech and healthcare.

AbbVie calls time on Reata alliance, claims $330m payback

AbbVie calls time on Reata alliance, claims $330m payback

PAH). Those are smaller markets than CKD/DKD, but according to Evaluate could still make bardoxolone a $1.3bn product in 2024 – which begs the question why AbbVie has decided to

Latest news

More from news
Approximately 5 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Six degrees of participation Six degrees of participation

    For example, our recent work to design a patient and carer mobile application for PAH has benefited from ongoing collaboration with clinicians, patient advocacy groups and leading tertiary centres across the

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck &Co grew cardiovascular revenues by 130%, while GSK enjoyed a 214% uplift, mainly due to its PAH treatment Volibris.

  • Pharma deals in September 2015 Pharma deals in September 2015

    In an attempt to be hunter rather than hunted, and to diversify its portfolio from just PAH (pulmonary arterial hypertension), Actelion has acknowledged it is holding “preliminary discussions with ZS Pharma”. ... complement Actelion's PAH portfolio.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... strong long-term growth potential to achieve leading positions in

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics